Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

[News]

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer-;as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib (Verzenio) in all patients, regardless of ESR1 mutation status-;according to results from the phase III EMBER-3 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

More... (https://www.news-medical.net/news/20241211/Imlunestrant-offers-new-hope-for-ER-positive-HER2-negative-breast-cancer.aspx)